Hui-Ying Rao1, Hong Li2, Hong Chen3, Jia Shang4, Qing Xie5, Zhi-Liang Gao6, Jun Li7, Yongtao Sun8, Jianning Jiang9, Lei Wang10, Longfeng Zhao11, Lunli Zhang12, Weibo Yang13, Junqi Niu14, Zuojiong Gong15, Guozhong Gong16, Ruifeng Yang1, Mei-Hsuan Lee17, Lai Wei1. 1. Peking University Hepatology Institute, Beijing Key Laboratory for Hepatitis C and Immunotherapy for Liver Disease, Peking University People's Hospital, Beijing. 2. Bristol-Myers Squibb, Wallingford. 3. The First Hospital of Lanzhou University, Lanzhou. 4. Henan Provincial People's Hospital, Zhengzhou. 5. Shanghai Ruijin Hospital, Jiaotong University School of Medicine, Shanghai. 6. The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou. 7. The First Affiliated Hospital of Nanjing Medical University, Nanjing. 8. Tangdu Hospital, Xi'an. 9. The First Affiliated Hospital of Guangxi Medical University, Nanning. 10. The Second Hospital of Shandong University, Jinan. 11. The First Affiliated Hospital of Shanxi Medical University, Taiyuan. 12. The First Affiliated Hospital of Nanchang University, Nanchang. 13. The First Affiliated Hospital of Kunming Medical University, Kunming. 14. The First Hospital of Jilin University, Changchun. 15. Renmin Hospital of Wuhan University, Wuhan. 16. The Second Xiangya Hospital of Central South University, Changsha. 17. Institute of Clinical Medicine, National Yang-Ming University, Taipei.
Abstract
BACKGROUND AND AIM: In China, chronic hepatitis C virus (HCV) infection represents a considerable healthcare burden. Although interferon-based therapy has been the standard-of-care for many years, few long-term, real-life studies have assessed interferon-based treatment in China. The objective of CCgenos follow-up study was to analyze long-term treatment patterns and outcomes in a cohort of treatment-naïve, Han ethnic, patients with chronic HCV infection. METHODS: Patients who had participated in the CCgenos cross-sectional study were invited to enter this 5-year follow up. Clinical information and centralized HCV-RNA measures were collected at scheduled study visits every 6 months for untreated patients and every 3 months for treated patients. RESULTS: Among 512 patients enrolled, 334 (65.2%) received interferon-based treatment and 178 (34.8%) remained untreated over a median of 4.1 (1.2-4.3) years. A total of 82.8% (424/512) of patients had an IL28B CC genotype (GT); 60.7% (311/512) had HCV GT1b infection, including 121 (38.9%) untreated. Most patients with baseline cirrhosis were untreated (26/46, 56.5%). Among patients who completed treatment and 24 weeks of post-treatment follow up, the duration of interferon-based therapy was frequently longer than recommended (52.9% [92/174] of GT1b-infected were treated for > 1 year). Rates of sustained virologic response (SVR24) were 71.1% (226/318) overall; 62.4% (111/178) among patients with HCV GT1b infection; and 42.9% (15/35) among patients with cirrhosis. CONCLUSIONS: There remains a high unmet need for effective HCV treatment in China, evidenced by a high proportion of patients remaining untreated by the current standard-of-care and relatively low SVR24 rates for patients with both GT1b infection and cirrhosis.
BACKGROUND AND AIM: In China, chronic hepatitis C virus (HCV) infection represents a considerable healthcare burden. Although interferon-based therapy has been the standard-of-care for many years, few long-term, real-life studies have assessed interferon-based treatment in China. The objective of CCgenos follow-up study was to analyze long-term treatment patterns and outcomes in a cohort of treatment-naïve, Han ethnic, patients with chronic HCV infection. METHODS:Patients who had participated in the CCgenos cross-sectional study were invited to enter this 5-year follow up. Clinical information and centralized HCV-RNA measures were collected at scheduled study visits every 6 months for untreated patients and every 3 months for treated patients. RESULTS: Among 512 patients enrolled, 334 (65.2%) received interferon-based treatment and 178 (34.8%) remained untreated over a median of 4.1 (1.2-4.3) years. A total of 82.8% (424/512) of patients had an IL28B CC genotype (GT); 60.7% (311/512) had HCV GT1b infection, including 121 (38.9%) untreated. Most patients with baseline cirrhosis were untreated (26/46, 56.5%). Among patients who completed treatment and 24 weeks of post-treatment follow up, the duration of interferon-based therapy was frequently longer than recommended (52.9% [92/174] of GT1b-infected were treated for > 1 year). Rates of sustained virologic response (SVR24) were 71.1% (226/318) overall; 62.4% (111/178) among patients with HCV GT1b infection; and 42.9% (15/35) among patients with cirrhosis. CONCLUSIONS: There remains a high unmet need for effective HCV treatment in China, evidenced by a high proportion of patients remaining untreated by the current standard-of-care and relatively low SVR24 rates for patients with both GT1b infection and cirrhosis.
Authors: Hui Jun Zhou; Jing Cao; Hui Shi; Nasheen Naidoo; Sherehe Semba; Pei Wang; Yi Fan Fan; Shui Cheng Zhu Journal: Front Public Health Date: 2021-12-09